MT Højgaard Holding A/S
MT Højgaard Holding A/S: Transactions in connection with share buy-back programme
On 23 November 2020, MT Højgaard Holding A/S announced that a share buy-back programme of an aggregated price of up to DKK 15,000,000 was launched with the purpose to meet obligations arising from the company’s share-based incentive programme.
The share buy-back programme is executed pursuant to the so-called ”Safe Harbour” provisions in Regulation (EU) No. 596/2014 of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016. The programme will end no later than on 30 September 2021.
The following transactions have been executed from 4 January to 8 January 2021:
| Number of
| Average purchase
|Accumulated, last announcement||12,620||156.83||1.979.172|
| 4 January 2021
5 January 2021
6 January 2021
7 January 2021
8 January 2021
|Accumulated under the programme||14,820||2,367,601|
A detailed overview of transactions executed during the period 4 January 2021– 8 January 2021 is attached to this announcement.
Following the above transactions, MT Højgaard Holding A/S owns a total of 14,820 treasury shares, corresponding to 0.190% of the company’s total share capital.
Contact: CFO Martin Stig Solberg may be contacted by phone on +45 2270 9365
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Synairgen plc25.1.2021 08:06:49 CET | Press release
Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients
F. Hoffmann-La Roche Ltd25.1.2021 08:06:08 CET | Press release
Roche renews partnership with Sysmex to deliver haematology testing solutions
Royal Philips25.1.2021 08:06:08 CET | Press release
Philips delivers Q4 sales of EUR 6.0 billion, with 7% comp. sales growth; income from cont. operations increases to EUR 608 million, Adjusted EBITA margin improves 110 bps to 19.0%, and operating cash flow increases to EUR 1,305 million
F. Hoffmann-La Roche Ltd25.1.2021 08:02:27 CET | Press release
Roche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration
Junshi Biosciences25.1.2021 08:01:47 CET | Press release
FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
Montreal Heart Institute23.1.2021 07:02:08 CET | Press release
Colchicine reduces the risk of COVID-19-related complications
Zealand Pharma22.1.2021 22:06:25 CET | Press release
Zealand Pharma announces update to 2020 financial guidance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom